Montelukast reduces sepsis-induced lung and renal injury in rats
- PMID: 25243774
- DOI: 10.1139/cjpp-2014-0191
Montelukast reduces sepsis-induced lung and renal injury in rats
Abstract
This study was undertaken to examine the effects of montelukast (MNT) on lung and kidney injury in lipopolysaccharide (LPS) induced systemic inflammatory response. Rats were randomized into 5 groups (n = 8 rats/group): (i) Control; (ii) LPS treated (10 mg/kg body mass, by intraperitoneal (i.p.) injection); (iii) LPS + MNT (10 mg/kg, per oral (p.o.)); (iv) LPS + MNT (20 mg/kg, p.o); (v) LPS + dexamethasone (DEX; 1 mg/kg, i.p.). Twenty-four hours after sepsis was induced, the lung or kidney:body mass ratio and percent survival of rats were determined. Creatinine, blood urea nitrogen (BUN), albumin, total protein, and LDH activity were measured. Lung and kidney samples were taken for histological assessment and for determination of their malondialdehyde (MDA) and glutathione (GSH) contents. The expression of tumour necrosis factor α (TNF-α) in tissue was evaluated immunohistochemically. LPS significantly increased the organ:body mass ratio, serum creatinine, BUN, and LDH, and decreased serum albumin and total protein levels. MDA levels increased in lung and kidney tissues after treatment with LPS, and there was a concomitant reduction in GSH levels. Immunohistochemical staining of lung and kidney specimens from LPS-treated rats revealed high expression levels of TNF-α. MNT suppresses the release of inflammatory and oxidative stress markers. Additionally, MNT effectively preserved tissue morphology as evidenced by histological evaluation. These results demonstrate that MNT could have lung and renoprotective effects against the inflammatory process during endotoxemia. This effect can be attributed to its antioxidant and (or) anti-inflammatory properties.
Keywords: dommage pulmonaire et rénal; inflammation; lipopolysaccharide; lung and kidney injury; montelukast; montélukast; oxidative stress; stress oxydant.
Similar articles
-
Montelukast attenuates lipopolysaccharide-induced cardiac injury in rats.Hum Exp Toxicol. 2016 Apr;35(4):388-97. doi: 10.1177/0960327115591372. Epub 2015 Jun 18. Hum Exp Toxicol. 2016. PMID: 26089034
-
Chronic renal failure-induced multiple-organ injury in rats is alleviated by the selective CysLT1 receptor antagonist montelukast.Prostaglandins Other Lipid Mediat. 2007 Jun;83(4):257-67. doi: 10.1016/j.prostaglandins.2007.01.013. Epub 2007 Jan 20. Prostaglandins Other Lipid Mediat. 2007. PMID: 17499745
-
The effects of montelukast against amikacin-induced acute renal damage.Eur Rev Med Pharmacol Sci. 2012 Apr;16(4):503-11. Eur Rev Med Pharmacol Sci. 2012. PMID: 22696878
-
Leukotriene receptor blocker montelukast protects against burn-induced oxidative injury of the skin and remote organs.Burns. 2005 Aug;31(5):587-96. doi: 10.1016/j.burns.2005.01.012. Burns. 2005. PMID: 15935562
-
Dysregulation of the immune response in severe sepsis.Am J Med Sci. 2004 Oct;328(4):220-9. doi: 10.1097/00000441-200410000-00005. Am J Med Sci. 2004. PMID: 15486537 Review.
Cited by
-
Inhibition of sepsis-induced pancreatic injury by leukotriene receptor antagonism via modulation of oxidative injury, and downregulation of inflammatory markers in experimental rats.Naunyn Schmiedebergs Arch Pharmacol. 2023 Nov 14. doi: 10.1007/s00210-023-02812-y. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2023. PMID: 37962585
-
Ameliorative effect of montelukast against STZ induced diabetic nephropathy: targeting HMGB1, TLR4, NF-κB, NLRP3 inflammasome, and autophagy pathways.Inflammopharmacology. 2024 Feb;32(1):495-508. doi: 10.1007/s10787-023-01301-1. Epub 2023 Jul 27. Inflammopharmacology. 2024. PMID: 37498374 Free PMC article.
-
Urinary Cysteinyl Leukotrienes as Biomarkers of Endothelial Activation, Inflammation and Oxidative Stress and Their Relationship with Organ Dysfunction in Human Septic Shock.Biomedicines. 2022 Nov 8;10(11):2845. doi: 10.3390/biomedicines10112845. Biomedicines. 2022. PMID: 36359365 Free PMC article.
-
Montelukast induces beneficial behavioral outcomes and reduces inflammation in male and female rats.Front Immunol. 2022 Sep 6;13:981440. doi: 10.3389/fimmu.2022.981440. eCollection 2022. Front Immunol. 2022. PMID: 36148246 Free PMC article.
-
Leukotriene Receptor Antagonist, Montelukast Ameliorates L-NAME-Induced Pre-eclampsia in Rats through Suppressing the IL-6/Jak2/STAT3 Signaling Pathway.Pharmaceuticals (Basel). 2022 Jul 24;15(8):914. doi: 10.3390/ph15080914. Pharmaceuticals (Basel). 2022. PMID: 35893738 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
